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Available online xxxxObjective: The aim of this study was to investigate interactions among pre-procedural aortic regurgitation (AR),
post-procedural paravalvular leak (PVL) and long-term clinical outcomes.
Methods and results:We analyzed data prospectively collected in the Italian Transcatheter balloon-Expandable
Registry (ITER) on aortic stenosis (AS) patients. The degree of pre-procedural AR and post-procedural PVL was
stratiﬁed as: absent/trivial, mild, and moderate/severe. VARC deﬁnitions were applied to outcomes. Of 1708 pa-
tients, preoperatively, AR was absent/trivial in 40% of the patients, mild in 42%, and moderate in 18%. Postoper-
atively, PVL was moderate–severe in 5%, mild in 32% of patients, and absent/trivial in 63%. Clinical follow-up,
median 821 days (IQR 585.75), was performed in 99.7% of patients. PVL, but not preoperative AR, was a major
predictor of adverse outcome (HR 1.33, CI 95% 0.9–2.05, p = 0.012 for mild PVL, HR 1.36, CI 95% 0.9–2.05,
p b 0.001 for PVL ≥moderate and OR 1.04, p= 0.97 respectively). Patients with moderate–severe PVL and pre-
operative left ventricle (LV) dilatation (LVEDVi N 75ml/m2) showed better survival than thosewithout dilatation
(HR 8.63, p= 0.001).
Conclusions: In patients with severe AS treated with balloon-expandable TAVI, the presence of PVL, but not pre-
procedural AR, was a major predictor of adverse outcome. Preoperative LV dilatation seemed to offer some clin-
ical advantages.
© 2017 Elsevier B.V. All rights reserved.Keywords:
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Transcatheter aortic valve implantation (TAVI) is a well-established
alternative to surgery in inoperable/high-risk patients with severe
symptomatic aortic stenosis (AS) [1–3]. Residual aortic regurgitation
(AR) due to paravalvular leakage (PVL) following TAVI is associated
with increased morbidity and mortality [3,4]. Despite technological ad-
vances in TAVI, the presence of any degree of PVL still remains a compli-
cation, the incidence of which varies between 2 and 40% [3–4,9–20],
regardless of prosthesis type [1–8]. However, the correlations among
pre-procedural AR, post-procedural PVL and long-term clinical out-
comes are not clearly known. Accordingly, we aimed to assess these po-
tential interactions and to investigate the role of preoperative AR and
left ventricle (LV) volumes in terms of long-term outcome in patients
with PVL after TAVI.
2. Methods
Between November 2007 and December 2012, patients with severe symptomatic AS
evaluated as being at high surgical risk or inoperable underwent TAVI at 33 Italian centers.
Patients with preoperative mitral regurgitation (MR) suitable for surgical correction were
not considered for the study. Indication for TAVI required consensus by themultidisciplin-
ary Heart Team of each center. All consecutive patients were included in the retrospective
voluntary Italian Transcatheter balloon-Expandable Registry (ITER) which complies withTable 1
Preoperative clinical features.
Variable Total (1708) PVL 0 (1083; 63.4
Age (years, median/I–III IQ) 82.5(78.4–86) 82.4(78.1–86)
Sex (%)
Female 1035 (61%) 688 (64%)
Male 673 (39%) 395 (36%)
Hypertension (%) 1381 (81%) 871 (80%)
Diabetes (%) 429 (25%) 272 (25%)
PVD (%) 595 (35%) 393 (36%)
COPD (%) 411 (24%) 261 (24%)
NYHA (%)
I 50 (3%) 30 (3%)
II 281 (16%) 160 (15%)
III 1177 (69%) 771 (71%)
IV 200 (12%) 122 (11%)
Neurological dysfunction (%) 145 (8%) 88 (8%)
EuroSCORE I (median/I–III IQ) 17(11.5–25.8) 17.2(11.5–25.6)
EuroSCORE II (median/I–III IQ) 5(3.2–9) 5.2(3.2–9)
STS Score (median/I–III IQ) 6.5(4.2–11.2) 6.6(4.3–11.5)
Cardiac rhythm (%)
SR 1129 (72%) 810 (75%)
AF 367 (21%) 205 (19%)
PPM 112 (7%) 68 (6%)
PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; SR: sinus rhy
Table 2
Preoperative echocardiographic features.
Variable Total (1708) PV
Maximum transaortic gradient (mm Hg, median/I–III IQ) 80 (67–95) 80
Mean transaortic gradient (mm Hg, median/I–III IQ) 49 (40–59 49
AVAi (cm2/m2, median/I–III IQ) 0.4 (0.4–0.5) 0.4
Aortic regurgitation (%)
0 676 (40%) 48
1 707 (42%) 40
2 312 (18%) 19
LVEDVi (mL/m2, median/I–III IQ) 72(55–96) 73
LVEF (%, median I–III IQ) 55 (46–61) 56
IVS thickness (mm, median/ I–III IQ) 14 (13–15) 13
Mitral regurgitation (%)
0 590 (35%) 40
1 702 (41%) 42
2 404 (24%) 24
sPAP (mm Hg, median/I–III IQ) 40 (33–50) 40
AVAi: aortic valve area indexed; LVEDVi: left ventricular end-diastolic volume indexed; LVEF: le
monary artery pressure., IQ: interquartile.
Please cite this article as: A. Colli, et al., Does pre-existing aortic regurgitati
TAVI?, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.2017.02.005the Declaration of Helsinki andwas approved by a locally appointed ethics committee. Pa-
tients gave written informed consent for participation in the Registry. Any type of access
was used. All procedures were performed with the balloon-expandable Edwards-SAPIEN
valve prosthesis (Edwards Lifesciences, Irvine, CA), Sapien and Sapien XT. Clinical and
echocardiographic data were prospectively recorded and subsequently analyzed.
Preoperative echocardiographic screening for the analysis of aortic valve functionwas
performed by means of transthoracic echocolor-Doppler (TTE); AR was graded in accor-
dance with guidelines as: absent (0), mild (grade 1) or moderate/severe (grade ≥ 2) [21].
The severity of PVL after TAVI was assessed by TTE at discharge, using a combination
of qualitative and semiquantitative parameters according to current guidelines [22,23]
and was graded as absent (0), mild (grade 1), or moderate/severe (grade ≥ 2). Adverse
events were adjudicated according to the VARC deﬁnitions [24].
3. Statistical analysis
Continuous variables were expressed as medians, with interquartile
range as a measure of variability. Survival curves were generated by
means of the Kaplan-Meier method and compared by means of the
log-rank test.
The association of factors with PVL status was modeled using a pro-
portional odds model whereas the individual effect of clinical data on
long-term survival was evaluated through Cox proportional hazards re-
gression analysis.
The proportional hazard assumption was checked by means of the
Grambsh and Therneau test and diagnostic plots were based on the%) PVL 1 (539; 31.6%) PVL 2 (86; 5%) p value
82.8(78.9–86.4) 83.1(80.2–85.9) 0.187
302 (56%) 45 (52%) 0.004
237 (44%) 41 (48%)
438 (81%) 72 (84%) 0.725
135 (25%) 22 (26%) 0.994
176 (33%) 26 (30%) 0.230
133 (25%) 17 (20%) 0.613
18 (3%) 2 (2%)
104 (19%) 17 (20%) 0.137
353 (65%) 53 (62%)
64 (12%) 14 (16%)
47 (9%) 10 (12%) 0.519
17.1(12.1–26.9) 15.4(11.2–23) 0.451
5(3.4–9.2) 3.7(2.3–5.9) 0.016
6.5(4.5–11) 6.9(3.8–10) 0.803
356 (66%) 63 (73%) 0.006
144 (27%) 18 (21%)
39 (7%) 5 (6%)
thm, AF: atrial ﬁbrillation, PPM: permanent pace- maker; IQ: interquartile.
L 0 (1083; 63.4%) PVL 1 (539; 31.6%) PVL 2 (86; 5%) p value
(67–95 77 (65–93.5) 84 (100–70) 0.065
(40–60) 47 (39.8–57) 50 (44–62) 0.026
(0.3–0.5) 0.5 (0.4–0.6) 0.4 (0.3–0.5) b0.001
1 (45%) 168 (31%) 27 (31%)
0 (37%) 266 (50%) 41 (48%) b0.001
2 (18%) 102 (19%) 18 (21%)
(56–97.8) 68 (52–88) 83 (54.5–99.8) 0.082
(47–62) 55 (45–60) 55 (45.8–60) 0.004
(12–15) 14 (13–15) 15 (13–16) 0.011
4 (38%) 167 (31%) 19 (22%)
9 (40%) 226 (42%) 47 (55%) 0.008
1 (22%) 143 (27%) 20 (23%)
(32–49) 40 (35–50) 40.5 (33–50) 0.325
ft ventricular ejection fraction; IVS: interventricular septum thickness; sPAP: systolic pul-
on protect from death in patients who develop paravalvular leak after
Table 3
Intra-procedural and post-procedural complications.
Variable Total (1708) PVL 0 (1083; 63.4%) PVL 1 (539; 31.6%) PVL 2 (86; 5%) p value
Prosthesis embolization (%) 5 (0.3%) 5 (0.5%) 0 (0%) 0 (0%) 0.235
ECC/ECMO (%) 7 (0.4%) 6 (0.6%) 1 (0.2%) 0 (0%) 0.456
Conversion to full sternotomy (%) 13 (0.8%) 11 (1%) 2 (0.4%) 0 (0%) 0.236
Apex bleeding/rupture (%) 23 (1.3%) 15 (1.4%) 8 (1.5%) 0 (0%) 0.532
CA/CPR (%) 28 (1.6%) 19 (1.8%) 7 (1.3%) 2 (2.3%) 0.695
Coronary ostia occlusion (%) 12 (0.7%) 10 (0.9%) 1 (0.2%) 1 (1.2) 0.214
Aortic dissection (%) 6 (0.4%) 6 (0.6%) 0 (0%) 0 (0%) 0.176
POAF (%) 152 (8.9%) 98 (9%) 45 (8.3%) 9 (10.5%) 0.802
AMI (%) 15 (0.9%) 12 (1.1%) 1 (0.2%) 2 (2.3%) 0.188
Bleeding (%)
Life threatening 128(7.5%) 92 (8.5%) 30 (5.6%) 6 (7%) 0.248
Major 186(10.9%) 119 (11%) 58 (10.8%) 9 (10.5%)
Minor 103 (6%) 56 (5.2%) 41 (7.6%) 6 (7%)
Vascular complications (%)
Major 133 (8%) 87 (8%) 40 (7%) 6 (7%) 0.561
Minor 120 (7%) 69 (6%) 46 (9%) 5 (6%)
Stroke (%)
TIA 16 (1%) 9 (1%) 6 (1%) 1 (1%)
Minor 11 (0.7%) 6 (1%) 4 (1%) 1 (%) 0.792
Major 12 (0.7%) 10 (1%) 2 (0.4%) 0 (0%)
New PPM (%) 104 (6%) 67 (6%) 34 (6%) 3 (3%) 0.538
Creatinine peak level at 72 h (m/dL, median, I–III IQ) 1.2 (0.9–1.6) 1.1 (0.9–1.5) 1.2 (0.9–1.6) 1.2 (1–1.6) b0.001
CVVH (%) 29 (2%) 14 (1%) 11 (2%) 4 (5%) 0.040
ECC: extracorporealcirculation; ECMO: extracorporeal membrane oxygenator; CA: cardiacarrest; CPR: cardio-pulmonaryresuscitation; POAF: postoperativeatrialﬁbrillation; AMI: acute
myocardialinfarction; TIA: transientischemicattack; PPM: permanent pace-maker; CVVH: continuous veno-venous hemoﬁltration; IQ: interquartile.
Table 4
Discharge echocardiographic data.
Variable Total (1708) PVL 0 (1083; 63.4%) PVL 1 (539; 31.6%) PVL 2 (86; 5%) p value
Maximum transaortic gradient (mm Hg, median/I–III IQ) 19 (24–15) 19 (15–24) 18 (14–23) 19 (16–25.3) 0.018
Mean transaortic gradient (mm Hg, median/I–III IQ) 10 (8–13) 10 (8–13) 10 (8–12) 11 (8–14) 0.005
LVEF (%, median/I–III IQ) 55 (50–61) 58 (50–62) 55 (48–60) 55 (50–60) b0.001
sPAP (mm Hg, median/I–III IQ) 35 (30–42) 35 (30–42) 35 (30–43) 37 (30–45) 0.391
Mitral regurgitation (%)
0 501 (38%) 370 (46%) 116 (26%) 15 (19%)
1 648 (49%) 342 (43%) 257 (59%) 49 (62%) b0.001
2 170 (13%) 90 (11%) 65 (15%) 15 (19%)
LVEF: left ventricle ejection fraction; sPAP: systolic pulmonary artery pressure; IQ: interquartile.
3A. Colli et al. / International Journal of Cardiology xxx (2017) xxx–xxxShoenfeld residual. All variables considered were entered into the
model as they were, without any transformation or cut-off. The nonlin-
ear effect of covariates was modeled by means of a restrictive cubic
spline function, and its signiﬁcance was assessed by means of the χ2
Wald test. Themodel strategywas determined by following a backward
selection strategy among variables reaching a level of at least 0.25 on
univariable analysis. Model ﬁt was considered signiﬁcantly improved
on the basis of the Akaike Information Criterion (AIC) applied backward
for each model at a signiﬁcance level of 0.05. To avoid inﬂation in type-I
error due tomultiplicity of testing, subgroup analysis was conducted by
introducing interaction terms into themainmultivariablemodel, and its
signiﬁcance assessed by means of AIC [25]. Multivariable models were
depicted as nomograms, estimated at different survival points (twoTable 5
Follow-up data.
Variable Total (1708) PVL 0 (1083; 63.4%
Overall mortality (%) 435 (25%) 252 (23%)
Cardiovascular mortality (%) 164 (10%) 92 (9%)
NYHA class (%)
I 517 (46%) 337 (50%)
II 474 (42%) 267 (40%)
III 115 (10%) 61 (9%)
IV 15 (1%) 7 (1%)
NYHA: New York Heart Association.
Please cite this article as: A. Colli, et al., Does pre-existing aortic regurgitati
TAVI?, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.2017.02.005and six years). To evaluate the goodness of ﬁt of the models, cross-
validation and bootstrap (1000 runs) techniques were applied by the
use of Somere option. Statistical signiﬁcance was set at p ≤ 0.05. The
R-System [26] statistical package and the HarrellorNrms [27] libraries
were used for analysis.
4. Results
Of the 1904 patients enrolled in the ITER, 191 patients (10%) died
within the ﬁrst 30 postoperative days and were excluded from the
study owing to the lack of long-term follow-up. Of these patients only
10 (5.2%) presented moderate PVL and 18 (9.4%) presented a mild
PVL, none presented severe PVL. Of those only 3 patients (1.6%)) PVL 1 (539; 31.6%) PVL 2 (86; 5%) p value
158 (29%) 25 (29%) 0.054
63 (12%) 9 (11%) 0.593
164 (42%) 16 (28%)
174 (45%) 33 (57%) 0.013
46 (12%) 8 (14%)
7 (2%) 1 (2%)
on protect from death in patients who develop paravalvular leak after
Fig. 1. Kaplan-Meier curve for overall survival according to PVL (0 = no PVL, 1 = mild PVL, 2 = moderate PVL).
Table 6
Independent risk factors for mortality during follow-up on multivariate analysis. Age and
gender were always included in the model. Somer's Dxy 0.53. Values are hazard ratios
(HR) and their corresponding conﬁdence intervals. p-Value refers to the signiﬁcance of
the variable in the ﬁnal model.
Factor HR 95% C.I. p value
LVEF ≤ 30% 1.82 1.24–2.66 0.002
Logistic EuroSCORE II 1.28 1.17–1.41 b0.001
Age 0.99 0.87–1.12 0.880
Male sex 1.37 1.13–1.66 0.001
Mild PVL 1.33 1.09–1-63 0.012
PVL ≥ moderate 1.36 0.90–2.05 b0.001
Preoperative AR 1.02 0.83–1.24 0.854
4 A. Colli et al. / International Journal of Cardiology xxx (2017) xxx–xxxpresented a more than moderate postoperative PVL. Another 5 patients
(0.3%) were excluded because they were lost to follow-up. A total of
1708 patients (89.7% of the original cohort) were available for the pur-
poses of the present study. Long term echocardiographic follow-upwas
complete in 1595 patients (94%).Fig. 2. Predictive nomogram to estimate long-term survival (based on independent risk factor
ranging from 0 to 100. The sum of each score can estimate the 2-years and 6-years survival pr
Please cite this article as: A. Colli, et al., Does pre-existing aortic regurgitati
TAVI?, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.2017.02.005Median age was 82.5 years (IQR 7.6); 61% were female. The medi-
an Euroscore II was 5 (IQR 5.8). Clinical follow-up (FU) was accom-
plished in 99.7% of patients, with a median FU time of 821 days
(IQR 586). Preoperatively, New York Heart Association (NYHA) clin-
ical functional class was ≥3 in 1377 (81%) patients. Before TAVI, 40%
of the patients had no AR, 42% mild AR and 18% moderate AR. After
TAVI, 63% of the patients had trace PVL or no PVL, 32% had mild
PVL and 5% had moderate–severe PVL. Tables 1 and 2 show preoper-
ative, clinical and echocardiographic data according to the different
degrees of PVL. Operative and postoperative complications are
shown in Table 3. Patients with greater PVL were more frequently
male (p = 0.004) and had higher creatinine levels (p = 0.006),
lower EuroSCORE II (p = 0.016), higher mean transvalvular gradi-
ents (p= 0.026), more reduced EF (p= 0.004), and LV hypertrophy
(p = 0.011).
Prosthesis sizes and the rate of the transfemoral approachwere sim-
ilarly distributed among PVL groups. Procedural complicationswere not
different among the groups. Only the rate of post-procedural renal in-
sufﬁciency requiring continuous veno-venous hemoﬁltration (CVVH)s: LVEF b 30%, EuroSCORE II, age, sex, PVL grade). Every variable is weighted with points
obability.
on protect from death in patients who develop paravalvular leak after
5A. Colli et al. / International Journal of Cardiology xxx (2017) xxx–xxxand creatinine peak levels at 72 hwere higher in patients with PVL (p=
0.040 and p b 0.001, respectively). After TAVI, patients with PVL had
higher maximum and mean valvular gradients (p = 0.018 and p =
0.005) and lower LVEF (p b 0.001).Fig. 3. Survival of patients according to the degreeof PVL (Panel A=noPVL, Panel B=mild PVL,
2 = moderate AR).
Please cite this article as: A. Colli, et al., Does pre-existing aortic regurgitati
TAVI?, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.2017.02.005We observed a reduction of mitral regurgitation severity in each
group; this reductionwas less evident in patientswithmoderate/severe
PVL. Complete postoperative echocardiographic data are shown in
Table 4.Panel C=moderate PVL) andby the presence of preoperativeAR (0=noAR, 1=mild AR,
on protect from death in patients who develop paravalvular leak after
6 A. Colli et al. / International Journal of Cardiology xxx (2017) xxx–xxxOn FU, overall mortality was 25% (435/1708). Patients with PVL suf-
fered higher mortality than those without PVL (29% vs. 23%, p = 0.05)
(Table 5). The overall survival rates according to the different degrees
of PVL are shown in Fig. 1. Overall mortality was similar for patients
with bothmild andmoderate PVL and signiﬁcantly higher than patients
without PVL (p b 0.001). Multivariable analysis demonstrated that PVL,
EuroSCORE II, reduced LV ejection fraction and male gender were inde-
pendent risk factors for death (Table 6, Fig. 3). Clinical status (NYHA
class) was affected by the presence of PVL (p = 0.01) (Table 5). (See
Fig. 2.)5. Preoperative AR, PVL and outcomes
Pre-existing AR was signiﬁcantly associated with higher levels of
PVL (OR for higher PVL levels 1.74, CI 95%, 1.33–2.28). The presence of
preoperative AR was not an independent predictor of outcome (HR =
1.02; CI 95% 0.83–1.24, p = 0.85). In patients with PVL, pre-existing
AR offered no advantage in terms of either survival (Fig. 3, Panels B
and C) or functional status [NYHA functional class, (OR = 0.73; CI 95%
0.13–4; p= 0.88)].
Considering the natural pathophysiologic remodeling of the LV in
the presence of pre-existing AR, we investigated the correlation be-
tween LV volumes [estimated by means of left ventricular end-
diastolic volume (LVEDVi)] and long-term survival in patients with
PVL of any degree. The presence of LV dilatation before TAVI seemed
to offer some clinical advantage. Speciﬁcally, a protective effect seemed
to emerge at values above 75mL/m2 (Fig. 4). In patients with postoper-
ative PVL, an enlarged LV is protective in term of mortality with a stron-
ger impact with the increasing of LVEDVi after the cutoff of 75 ml/m2.
More speciﬁcally, to evaluate the real impact of LVdilatation on survival,
we divided the study population into two subgroups, according to the
type of aortic valve pathology: group A comprising patients with isolat-
ed severe AS (trace andmild [1+] ARwere included) and group B com-
prising those with combined aortic valve disease (severe AS with
concomitant AR equal or greater than moderate [2+]). On comparing
the two groups, we observed that in patients with isolated AS, the pres-
ence of LV dilatationwas associatedwithworse prognosis in case of PVL
equal or greater thanmoderate (Fig. 5-Panel A, Log Relative Hazard N 0).
By contrast in case of PVL equal or greater thanmoderate progressive LVFig. 4. Effect of left ventricular dilatation on patients according to PVL (no/mild PVL; mode
Please cite this article as: A. Colli, et al., Does pre-existing aortic regurgitati
TAVI?, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.2017.02.005dilatation was protective in the group with combined disease (Fig. 5-
Panel B, Log Relative Hazard b 0).
6. Discussion
The main ﬁndings of our analysis of the interactions among pre-
procedural aortic regurgitation (AR), LV dilatation, post-procedural
PVL and long-term clinical outcomes of patients treated with balloon-
expandable TAVI were that: 1) PVL was an independent risk factor for
poor long-term outcome; 2) preoperative AR was associated with
higher levels of PVL; 3) preoperativeARwas not an independent predic-
tor of outcome in patients who developed PVL; and 4) in patients with
PVL, the presence of preoperative LV dilatation before TAVI seemed to
be of some clinical advantage in those with combined aortic valve dis-
ease, and to be disadvantageous in those with isolated aortic stenosis.
PVL is the Achilles' heel of TAVI. Indeed, many studies have demon-
strated its negative effect on both short- and long-term survival [17,
28–32]. This effect is one of the most important obstacles to extending
TAVI to younger and intermediate-risk patients. The present study con-
ﬁrmed previous ﬁndings that mild PVL is common after TAVI proce-
dures, and that moderate to severe PVL is less frequent.
It was formerly believed that onlymoderate and severe PVLwere in-
dependent risk factors formortality. Reports by Kodali [16,18], however,
have shown that mild PVL also has a negative impact on survival. This is
consistent with our ﬁndings, which indicated that the presence of post-
operative PVL, independently of its severity, was a risk factor for overall
long-term mortality (OR 7.5, p = 0.02). These ﬁndings are consistent
with those reported by other authors [4–9]. Our multivariate analysis
was performed both on including and on excluding preoperative AR.
Differently from ﬁndings reported by Van Belle in FRANCE2 Registry
[33], in our series preoperative AR did not prove to be an independent
risk factor for all-cause death, nor did it modify the impact of other var-
iables on long-term survival.
Present results may suggest performing a population matched anal-
ysis to overcome the potential limitation related to a large retrospective
multicenter registry. We observed a signiﬁcative reduction of MR grade
after the procedure but this modiﬁcation was less evident in patients
with moderate/severe PVL probably because of the maintenance of a
volume overload due to the PVL itself. This lower reduction could act
as another risk factor for the higher long-term mortality observed inrate PVL); Log Relative Hazard values inferior than 0 are related to improved survival.
on protect from death in patients who develop paravalvular leak after
Fig. 5. Effect of left ventricular dilatation inpatients according to aortic valve disease (Panel A= isolated aortic valve stenosis; Panel B=combined aortic valve disease) and by grade of PVL
(0 = no PVL, 1 = mild PVL, 2 = moderate or greater PVL); Log Relative Hazard values inferior than 0 are related to improved survival.
7A. Colli et al. / International Journal of Cardiology xxx (2017) xxx–xxxthis group. Anyway, at multivariate analysis, the presence of postopera-
tiveMRdid not result as signiﬁcative independent risk factor formortal-
ity. Interestingly, we have observed that patients who presented
postoperative PVL presented also a higher incidence of acute renal inju-
ry (higher creatinine peak levels at 72 h and use of CVVH).We can spec-
ulate that this new observation could be related to the greater amount
of contrast used to evaluate the severity of PVL immediately after TAVI
implantation and/or after balloon post dilatation used to correct PVL.
Unfortunately, the information on contrast and requirement of post di-
latation were not collected in the ITER registry.
Ourﬁndings revealed an association between the presence of preop-
erative AR and the development of post-procedural PVL. One possiblePlease cite this article as: A. Colli, et al., Does pre-existing aortic regurgitati
TAVI?, Int J Cardiol (2017), http://dx.doi.org/10.1016/j.ijcard.2017.02.005explanation is that patients with AS associatedwith relevant AR present
in general a signiﬁcant fusion of the commissures. In this situation the
prosthesis deployment could result asymmetrical due to the different
resistance offered by the calciﬁed commissures to the valve stent
frame. This ﬁnding is in accord to the literature reporting that heavy
and asymmetrical calciﬁcation of the aortic annulus and aortic leaﬂets
can be considered one of the risk factors for post-procedural PVL [16,
17].
Based on the pathophysiology of aortic valve disease, we hypothe-
sized that the existence of concomitant preoperative AR could, as a re-
sult of LV adaptation to long-standing volume overload, act as a
protective factor in patients who developed PVL. The present studyon protect from death in patients who develop paravalvular leak after
8 A. Colli et al. / International Journal of Cardiology xxx (2017) xxx–xxxdid not conﬁrm our hypothesis; indeed, we observed that preoperative
AR did not improve survival in the event of PVL.
By contrast, LV dilatation with LVEDVI greater than 75 ml/m2 was
identiﬁed as a protective factor. The clinical advantage, considered as
improved long-term survival, is related to the presence of preoperative
LV dilatation in patients who develops more than mild PVL with a pro-
gressive stronger effect in case of higher LVEDVi values. To better deﬁne
the importance of LV dilatation, we performed a subgroup analysis
based on the type of aortic valve disease.We hypothesized that patients
with pure AS could present LV dilatation as result of a different patho-
physiologicmechanism from that acting in patients with combined aor-
tic valve disease. Indeed, in the case of isolated AS, the presence of LV
dilatation reduced long-term survival, while in the case of combined
disease, it improved survival.
In patientswith AS, LVEDVi does not increase and high-pressure gra-
dients between the LV and the aorta determine LV hypertrophy. This re-
sults in impaired relaxation, increased stiffness, myocardial ﬁbrosis and
elevated LV end-diastolic pressure, making it difﬁcult to manage the
acute volume overload that occurs in the event of PVL. In patients
with concomitant AR, by contrast, the volume overload causes an in-
crease of LVEDVi. Thanks to LV compliance and progressive eccentric
ventricular remodeling, LV end-diastolic pressure does not increase,
making the volume overload determined by PVL tolerable.
The present observations are also supported by a recent publication
by Ewe et al. [34], in which it was demonstrated that LV stiffness (mea-
sured as interventricular septum thickening) impacted negatively on
the survival of patients with PVL.7. Limitations
Possible limitations of our study are: 1) data from a retrospective
registry, 2) the small number of patients with severe AR combined
with AS, 3) the lack of data on LV wall thickness and ﬁlling pressure
values, from which to estimate the real LV wall stress and diastolic per-
formance, and 4) the lack of a core-lab evaluation of preoperative and
postoperative Echocardiographic data. The impact of this item was re-
duced by the strict application of VARC international criteria for the clas-
siﬁcation of the severity of preoperative AR and postoperative PVL.8. Conclusions
The postoperative presence of any grade of PVL negatively affects
both overall survival and functional class.
Pre-existing AR has no protective effect on survival in the event of
post-procedural PVL. LV dilatation has a protective effect on long-term
survival in patients with mixed valvular pathology who develop at
least a moderate degree of PVL. Dilatation due to prolonged pure AS
does not display the same effect.9. Impact on daily practice
PVL is a challenging complication of TAVI and has signiﬁcant impact
on survival. We tried to identify the type of patients in whom a more
than mild postoperative PVL could be accepted. Our ﬁndings demon-
strate that preexisting AR in a AS patient is never a protective factor;
but patients with AS, AR and LV dilatation are those who best tolerate
post procedural AR at long-term FU.Conﬂict of interest
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